---
title: "Cysteine (N‑acetylcysteine) reverses immune dysfunction in cancer patients with severe COVID‑19"
id: "medrxiv-7-cysteine-supplementation-reverses-immune-dysfunction-in-cancer-patients-with"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-cysteine-supplementation-reverses-immune-dysfunction-in-cancer-patients-with"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.21.26363550v1?rss=1"
published_at: "2026-09-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cysteine (N‑acetylcysteine) reverses immune dysfunction in cancer patients with severe COVID‑19
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-cysteine-supplementation-reverses-immune-dysfunction-in-cancer-patients-with
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.21.26363550v1?rss=1)
- **Published At:** 2026-09-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Severe COVID-19 in patients with cancer shows a distinct pattern of immune dysfunction characterized by muted adaptive immune responses compared with non-cancer patients. - Integrated **proteomic** and **metabolomic** profiling of matched cohorts identified dysfunctional **cysteine metabolism** as uniquely associated with severe COVID-19 in cancer patients. - A single‑institution phase II prospective trial (ClinicalTrials.gov NCT04374461) treated steroid‑refractory hospitalized cancer patients with **N‑acetylcysteine (N‑AC)**; trial details and IRB approval were reported. - Compared with disease severity–matched hospitalized patients from the immediately preceding period, N‑AC treatment improved clinical outcomes in the treated cohort. - N‑AC therapy reduced circulating markers of innate inflammation and decreased the population of severe disease–associated **MHC‑II low monocytes**. - Treatment increased circulating **CD8+ T cell** abundance, activation, and effector differentiation in treated patients. - Mechanistic studies indicated N‑AC reduced **prostaglandin E2 (PGE2)**‑driven interactions between suppressive monocytes and T cells, which limited T cell expansion and effector differentiation in a dose‑ and avidity‑dependent manner. - N‑AC lowered activity of inhibitory, redox‑sensitive transcription factors such as **KLF6**, facilitating clonal expansion and effector T cell differentiation. - Two murine models of severe respiratory viral infection replicated key findings: N‑AC increased lung‑infiltrating CD8+ T cell abundance. - Authors conclude cysteine supplementation is a viable strategy to reverse redox‑driven immune dysregulation in severe respiratory viral infection, particularly for the high‑risk cancer population. - Trial allowed concomitant anti‑COVID therapies (steroids, antivirals, monoclonal antibodies, convalescent plasma, tocilizumab); sequencing data planned for dbGaP at publication; clinical data available from corresponding author on request.
## Clinical Analysis & Structured Key Points
Cysteine supplementation reverses immune dysfunction in cancer patients with severe COVID-19 | medRxiv Skip to main content Cysteine supplementation reverses immune dysfunction in cancer patients with severe COVID-19 Tiffany Merlinsky , Jahan Rahman , William T Johnson , Lisa McGary , Simon Grassmann , Jennifer Zhang , Abdulraouf Abdulraouf , Hannah L Kalvin , Katherine Panageas , Jasmine Nicodemus , Elizabeth Cathcart , Ya-Hui Lin , Kinga K Hosszu , Mirela Berisa , Olga Lyudovyk , Gilles Salles , Jaap J Boelens , N Esther Babady , Junyue Cao , Jedd D Wolchok , Joseph C Sun , James Heath , Benjamin Greenbaum , View ORCID Profile Santosha Vardhana doi: https://doi.org/10.64898/2026.09.21.26363550 Tiffany Merlinsky 1 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jahan Rahman 1 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site William T Johnson 2 Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lisa McGary 1 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Simon Grassmann 3 Immunology Program, Sloan Kettering Institute for Cancer Research; New York, NY, USA.; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jennifer Zhang 3 Immunology Program, Sloan Kettering Institute for Cancer Research; New York, NY, USA.; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abdulraouf Abdulraouf 4 Laboratory of Single Cell Genomics and Population Dynamics, The Rockefeller University; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hannah L Kalvin 5 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Katherine Panageas 5 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jasmine Nicodemus 2 Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elizabeth Cathcart 2 Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ya-Hui Lin 1 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kinga K Hosszu 6 Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mirela Berisa 7 Metabolomics Core, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Olga Lyudovyk 8 Memorial Sloan Kettering Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Gilles Salles 2 Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jaap J Boelens 6 Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site N Esther Babady 9 Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Junyue Cao 4 Laboratory of Single Cell Genomics and Population Dynamics, The Rockefeller University; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jedd D Wolchok 10 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Joseph C Sun 3 Immunology Program, Sloan Kettering Institute for Cancer Research; New York, NY, USA.; Find this author on Google Scholar Find this author on PubMed Search for this author on this site James Heath 11 Institute for Systems Biology; Seattle, WA, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Benjamin Greenbaum 5 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Santosha Vardhana 1 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Santosha Vardhana For correspondence: vardhans{at}mskcc.org Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Severe COVID-19 infection in patients with cancer is characterized by a unique pattern of immunologic dysfunction including muted adaptive immune responses. The molecular drivers of immune dysfunction in cancer patients with severe COVID-19 remain unclear, and therapeutic strategies to overcome immune dysfunction in this setting have not been identified. We performed integrated proteomic and metabolomic profiling of matched cohorts of cancer and non-cancer patients with or without COVID-19 and identified dysfunctional cysteine metabolism as uniquely associated with severe COVID-19 in cancer patients. Treatment of patients with cancer and steroid-refractory COVID-19 with N-acetylcysteine in a prospective clinical trial ( NCT04374461 ) improved clinical outcomes compared with disease severity-matched hospitalized patients during the period immediately preceding clinical trial initiation. N-AC treatment reduced circulating markers of innate inflammation, decreased severe disease-associated MHC-II low monocytes, and increased circulating CD8+ T cell abundance, activation, and effector differentiation. Mechanistically, N-AC reduced prostaglandin E2-driven interactions between suppressive monocytes and T cells, which we confirmed was sufficient to limit T cell expansion and effector differentiation in a dose- and avidity-dependent fashion. Moreover, N-AC reduced the activity of inhibitory, redox sensitive transcription factors such as KLF6, enabling clonal expansion and effector T cell differentiation. We confirmed these observations in two murine models of severe respiratory viral infection, in which N-AC treatment significantly enhanced lung-infiltrating CD8+ T cell abundance. These findings establish cysteine supplementation as a viable therapeutic strategy to reverse redox-driven immune dysregulation in severe respiratory viral infection, particularly in the high-risk cancer population. Competing Interest Statement SAV previously served as an advisor for Immunai and GenerateBio and has received consulting fees from Koch Disruptive Technologies, as well as research funding from Bristol Myers Squibb unrelated to the present study. JDW is a consultant for Ankyra Therapeutics, Apricity, Arsenal Biosciences, Ascentage Pharma, Bicara Therapeutics, Bristol Myers Squibb, Daiichi Sankyo, Imvaq, Larkspur, Takeda, Tizona, Trishula Therapeutics, Immunocore: Data Safety board, and Scancell. JDW has received research support from Bristol Myers Squibb. JDW has equity in Apricity, Arsenal IO/CellCarta, Ascentage, Imvaq, Linneaus, Georgiamune, Maverick/Takeda, Tizona Therapeutics, and Xenimmune. SAV was supported by the Josie Robertson Investigators Program. BG has received honoraria for speaking engagements from Merck, Bristol Meyers Squibb, and Chugai Pharmaceuticals; has received research funding from Bristol Meyers Squibb and Merck; and has been a compensated consultant for Darwin Health, Merck, PMV Pharma and Rome Therapeutics of which he is a co-founder. The other authors declare that they have no competing interests. Clinical Trial NCT04374461 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This was a single institution phase II study evaluating the efficacy of N-AC in hospitalized patients with severe COVID-19 infection. There were two arms to the trial. Arm A consisted of mechanically ventilated patients or patients admitted to the intensive care unit (ICU) (i.e., high concern for respiratory decompensation). Arm B consisted of patients requiring Supplementary oxygen of 2L of more by nasal cannula (to maintain an SpO2 of 95%) but not already admitted to the ICU. Other inclusion criteria required patients to have a documented COVID-19 infection and were ≥18 years of age. For arm A, it was also required that patients have an absolute lymphocyte count (ALC) of >1 cell/uL (patients with lymphoid malignancy were allowed to enroll regardless of ALC). Otherwise, there were no other strict inclusion or exclusion criteria. Patients were allowed to receive any form of concomitant anti-COVID therapies at any time point including steroids, anti-viral therapies, monoclonal antibodies, convalescent plasma, and tocilizumab. The protocol was approved by the Memorial Sloan Kettering internal review board (IRB) and registered on clinicaltrials.gov ( NCT04374461 ). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Sequencing data will be available on dbGaP at the time of publication. All clinical data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. All other data are available in the main text or the supplementary materials. Funder Information Declared National Institutes of Health, https://ror.org/01cwqze88 , F30HL175968 , T32GM152349 , P30CA008748 Pershing Square Sohn Cancer Research Alliance Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 22, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Cysteine supplementation reverses immune dysfunction in cancer patients with severe COVID-19 Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Cysteine supplementation reverses immune dysfunction in cancer patients with severe COVID-19 Tiffany Merlinsky , Jahan Rahman , William T Johnson , Lisa McGary , Simon Grassmann , Jennifer Zhang , Abdulraouf Abdulraouf , Hannah L Kalvin , Katherine Panageas , Jasmine Nicodemus , Elizabeth Cathcart , Ya-Hui Lin , Kinga K Hosszu , Mirela Berisa , Olga Lyudovyk , Gilles Salles , Jaap J Boelens , N Esther Babady , Junyue Cao , Jedd D Wolchok , Joseph C Sun , James Heath , Benjamin Greenbaum , Santosha Vardhana medRxiv 2026.09.21.26363550; doi: https://doi.org/10.64898/2026.09.21.26363550 Share This Article: Copy Citation Tools Cysteine supplementation reverses immune dysfunction in cancer patients with severe COVID-19 Tiffany Merlinsky , Jahan Rahman , William T Johnson , Lisa McGary , Simon Grassmann , Jennifer Zhang , Abdulraouf Abdulraouf , Hannah L Kalvin , Katherine Panageas , Jasmine Nicodemus , Elizabeth Cathcart , Ya-Hui Lin , Kinga K Hosszu , Mirela Berisa , Olga Lyudovyk , Gilles Salles , Jaap J Boelens , N Esther Babady , Junyue Cao , Jedd D Wolchok , Joseph C Sun , James Heath , Benjamin Greenbaum , Santosha Vardhana medRxiv 2026.09.21.26363550; doi: https://doi.org/10.64898/2026.09.21.26363550 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (905) Anesthesia (336) Cardiovascular Medicine (4838) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1634) Epidemiology (15986) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7073) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5074) Health Policy (1438) Health Systems and Quality Improvement (1780) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16316) Intensive Care and Critical Care Medicine (1177) Medical Education (674) Medical Ethics (155) Nephrology (727) Neurology (7318) Nursing (370) Nutrition (1088) Obstetrics and Gynecology (1245) Occupational and Environmental Health (1007) Oncology (3625) Ophthalmology (1058) Orthopedics (398) Otolaryngology (458) Pain Medicine (477) Palliative Medicine (140) Pathology (709) Pediatrics (1806) Pharmacology and Therapeutics (739) Primary Care Research (769) Psychiatry and Clinical Psychology (5927) Public and Global Health (9782) Radiology and Imaging (2438) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (644) Sexual and Reproductive Health (774) Sports Medicine (582) Surgery (783) Toxicology (107) Transplantation (306) Urology (295)
## Related Clinical Research

- [Integrative oncology works for cancer symptoms — insurers lag on coverage](https://medichelpline.com/clinical-feed/stat-news-4-opinion-the-science-on-relieving-cancer-symptoms-is-clear-why-isn-t-insurance.md)
- [Structured aerobic exercise linked to lower cancer recurrence and improved survival](https://medichelpline.com/clinical-feed/medical-news-today-0-aerobic-exercise-could-help-improve-outlook-after-cancer-treatment.md)
- [Sudan civil war damages hospitals, forcing cancer patients into dangerous journeys](https://medichelpline.com/clinical-feed/stat-news-2-in-sudan-attacks-on-hospitals-force-patients-to-make-dangerous-journeys.md)
- [Inferring tumor kinetics from single routine H&E biopsies to run virtual radiotherapy trials](https://medichelpline.com/clinical-feed/medrxiv-9-effective-tumor-kinetics-inferred-from-single-routine-h-e-biopsies-enable.md)
- [Daraxonrasib shows activity in RAS‑mutant NSCLC after FDA approval in pancreatic cancer](https://medichelpline.com/clinical-feed/medical-news-today-0-pancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.